ERBB2 and neoplasm: Even more recently, early results from the MyPathway study, evaluating the efficacy of 4 targeted treatments in 35 different tumor types with activating molecular alterations in the human epidermal growth factor receptor 2 (HER2), BRAF, epidermal growth factor receptor (EGFR), or Hedgehog pathways, were reported [15].